Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) have been given a consensus rating of “Buy” by the five research firms that are covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $25.72.

A number of research firms recently issued reports on ATNM. Maxim Group raised their price objective on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $6.56 on Friday. The stock has a market capitalization of $192.86 million, a PE ratio of -3.58 and a beta of 0.01. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million during the quarter. On average, equities research analysts anticipate that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Brandywine Global Investment Management LLC purchased a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $1,033,000. Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals during the first quarter worth approximately $78,000. 27.50% of the stock is currently owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.